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Temporal lobe epilepsy is the most common drug-resistant form of
epilepsy in adults. The reorganization of neural networks and the
gene expression landscape underlying pathophysiologic network
behavior in brain structures such as the hippocampus has been
suggested to be controlled, in part, by microRNAs. To systemati-
cally assess their significance, we sequenced Argonaute-loaded
microRNAs to define functionally engaged microRNAs in the hip-
pocampus of three different animal models in two species and at
six time points between the initial precipitating insult through to
the establishment of chronic epilepsy. We then selected commonly
up-regulated microRNAs for a functional in vivo therapeutic screen
using oligonucleotide inhibitors. Argonaute sequencing generated
1.44 billion small RNA reads of which up to 82% were microRNAs,
with over 400 unique microRNAs detected per model. Approximately
half of the detected microRNAs were dysregulated in each epilepsy
model. We prioritized commonly up-regulated microRNAs that were
fully conserved in humans and designed custom antisense oligonu-
cleotides for these candidate targets. Antiseizure phenotypes were
observed upon knockdown of miR-10a-5p, miR-21a-5p, and miR-142a-
5p and electrophysiological analyses indicated broad safety of this
approach. Combined inhibition of these three microRNAs reduced
spontaneous seizures in epileptic mice. Proteomic data, RNA sequenc-
ing, and pathway analysis on predicted and validated targets of these
microRNAs implicated derepressed TGF-β signaling as a shared
seizure-modifying mechanism. Correspondingly, inhibition of TGF-
β signaling occluded the antiseizure effects of the antagomirs. To-
gether, these results identify shared, dysregulated, and functionally
active microRNAs during the pathogenesis of epilepsy which repre-
sent therapeutic antiseizure targets.
antisense oligonucleotide | biomarker | epigenetic | epilepsy |
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Temporal lobe epilepsy (TLE) is characterized by seizuresarising from or involving the hippocampus and is the most
common focal epilepsy syndrome in adults (1). TLE is frequently
refractory to pharmacotherapy, often necessitating surgical resec-
tion of involved brain structures (2). The most common patholog-
ical finding within the removed hippocampus is select neuron loss
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and gliosis (3). Resected tissue from TLE patients also features
neuroinflammation and remodeling of neuronal networks at both
micro- and macroscopic scale (4, 5). Recent sequencing and array-
based profiling of protein-coding transcripts and systems biology
approaches have generated deep insights into the molecular path-
ophysiology and helped identify novel classes of molecule for
therapeutic targeting (6–9).
MicroRNAs (miRNAs) are critical for shaping the gene ex-
pression landscape in the brain (10). They are short noncoding
RNAs that primarily function posttranscriptionally, conferring
precision to cellular protein fluctuations (11, 12). Biogenesis of
miRNAs involves nuclear processing of a primary transcript
followed by terminal loop processing in the cytoplasm, resulting
in a miRNA duplex from which one strand is selected by an
Argonaute (Ago) protein (13). Argonaute-2 (Ago2) is critically
important for miRNA function, enriched in the hippocampus
and, uniquely among Ago proteins, can directly cleave target
RNAs (14). After miRNA loading and the formation of a RNA-
induced silencing complex (RISC), potential mRNA targets are
selected through imperfect base pairing between miRNA and
mRNA (15). Upon identifying regions of sufficient comple-
mentarity, typically 7- to 8-nt matches between the miRNA and
the 3′-untranslated region of the target mRNA, the RISC re-
cruits further proteins, leading to translational repression or
mRNA decay (16). Individual miRNAs often have multiple
targets, increasing the scope for influencing several pathways or
enhanced regulation of single pathways by multiple miRNAs,
which may be an advantage for the treatment of TLE (11, 12).
Spatiotemporal changes to miRNA expression have been reported
in the hippocampus following epileptogenic brain injuries and these
persist in established epilepsy (17, 18). In parallel, in vivo deployment
of oligonucleotide miRNA inhibitors (antagomirs) has demonstrated
functional roles for a few miRNAs in seizure control and epilepto-
genesis (19, 20). It remains unknown how many more miRNAs
may be suitable targets in epilepsy. Recent efforts have identified
miRNAs dysregulated in TLE (21–23) but no study to date has
focused on quantifying the amounts of functional Ago2-loaded
miRNAs that are shared between TLE models. This is important
since the specific enrichment for Ago2-loaded miRNAs provides
greater coverage of the miRNA landscape and better predicts the
regulatory potential of miRNAs (24).
Here, we performed small RNA sequencing (RNA-seq) of
Ago2-loaded miRNAs from three different animal models across
all phases of epilepsy development in two rodent species. Based
on this resource, we deployed an in vivo antagomir screen and
identified several antiseizure and neuroprotective phenotypes
among miRNAs that were up-regulated across the three models.
Pathway analysis combined with RNA sequencing and proteomic
analysis implicated derepressed TGF-β signaling as a potential
overlapping mechanism between the targeted miRNAs. In
agreement with this, inhibition of TGF-β signaling blocked the
antiseizure effects of the antagomirs. Our systems-level approach
identifies an extensive class of miRNAs that may prove target-
able for the treatment of seizures in human TLE.
Results
Ago2 Sequencing Provides a Quantitative Catalog of Functionally
Engaged miRNAs in Experimental TLE. To identify shared func-
tionally engaged miRNAs at each phase of epilepsy develop-
ment, we performed Ago2 immunoprecipitation followed by
small RNA sequencing on hippocampal samples from three
different rodent models of TLE in two species under continuous
electroencephalogram (EEG) monitoring, sampling tissue at six
time points (intraamygdala kainic acid [IAKA]: n = 18 treated
and 18 vehicle control; pilocarpine [PILO]: n = 18 treated and 18
vehicle control; perforant path stimulation [PPS]: n = 21 treated
and 3 nonstimulated control, total n = 96; Fig. 1A, SI Appendix,
Table S1, and Methods). This generated 1.44 billion small RNA
reads of which up to 82% were miRNAs, with over 400 unique
miRNAs detected per model (Fig. 1B and SI Appendix, Table
S2). There was exceptionally high concordance for levels among
the most abundant miRNAs, with sequencing reads often dif-
fering by as little as 1% across the three models (Fig. 1C).
Induction of epilepsy led to significant changes in the abundance
of approximately half of the detected miRNAs in the hippocampus
in each model (Fig. 2A and Dataset S1). Expression changes
showed disease stage-specific differences for individual miRNAs,
including up- and down-regulation shortly after the epileptogenic
insult, on the day of first spontaneous seizure and chronic epilepsy,
indicating that all phases of epilepsy development are associated
with specific miRNA changes (Fig. 2 A–C). For miRNAs that
originate from the same primary transcript, expression levels of
miRNAs within the cluster often followed similar patterns (Fig. 2C).
Next, we identified shared dysregulated (differential expression
>25%) miRNAs across the three models, excluding low-abundance
(<10 reads per million [RPM]) miRNAs for all time points analyzed
(Fig. 3A). Within the chronic epilepsy phase, the period most relevant
to how a miRNA-based therapeutic might be used clinically (i.e.,
treating patients with preexisting, refractory epilepsy) (17), we found
eight up- and one down-regulated miRNAs common to all three
models (Fig. 3 A–C). This included miR-132-3p and miR-146a-5p, for
which there are already significant functional data linking them to
epilepsy (25–28), and six miRNAs (miR-10a-5p, miR-21a-3p, miR-27a-
3p, miR-142a-5p, miR-212-3p, and miR-431-5p) for which there are
limited or no functional in vivo data linking to epilepsy (Fig. 3C).
In Vivo Antagomir Screening Identifies Three Antiseizure Phenotypes.
We hypothesized that the up-regulated miRNAs shared in the
chronic epilepsy phase across the three models would be enriched
for regulators of brain excitability, and we selected those which were
fully conserved in humans. To test this, we designed custom locked
nucleic acid (LNA)-modified oligonucleotide miRNA inhibitors
(antagomirs) and used these to assess seizure responses after in vivo
knockdown of miRNAs (Fig. 4 A and B). We excluded miR-132-3p
and miR-146a-5p to prioritize miRNAs not previously linked to
epilepsy and excluded miR-21a-3p because it is not fully conserved
in humans, therefore limiting translational potential. Instead, we
selected the fully conserved miR-21a-5p, which also satisfied basal
expression criteria and up-regulation (at least 15%) in all three
models. Mice received an intracerebroventricular injection of one of
six targeting antagomirs (Fig. 4B), a scrambled antagomir (Scr) or
vehicle (phosphate buffered saline [PBS]) 24 h before induction of
status epilepticus (SE) by an intraamygdala microinjection of kainic
acid (Fig. 4A). This procedure ensures an optimal miRNA knock-
down at the time of testing seizure responses (29). EEG recordings
were used to assess seizure severity and brains were later processed
to quantify irreversible hippocampal damage (29).
Seizure severity, as determined by analysis of EEG total power
(29), was significantly reduced during SE in mice preinjected with
antagomirs against miR-10a-5p, miR-21a-5p, and miR-142a-5p
(Fig. 4 C and D). Seizure burden, determined by measuring only
ictal epileptiform activity (29), was significantly reduced by the same
antagomirs and was also significant for antimiR-431-5p (Fig. 4E).
Analysis of the brains from mice killed 24 h after SE revealed sig-
nificant neuroprotection for five of the six antagomirs (those tar-
geting miRNAs -10a-5p, -21a-5p, -27a-5p, -142a-5p, and -431-5p),
relative to controls (Fig. 4 F and G). These results suggest that a
high proportion of the shared miRNAs up-regulated in the chronic
phase of experimental epilepsy may be maladaptive, contributing to
enhanced network excitability and neuronal damage. Consequently,
their targeting may offer approaches to control seizures.
Knockdown of miR-10a-5p, -21a-5p, and -142a-5p Has Limited Biophysical
and Functional Effects in Naïve Rat Brains. Current antiseizure drugs
are associated with side effects arising from nonspecific dampening
of brain excitability (1, 2). Focusing on the miRNAs which showed



























Fig. 1. Experimental design and small RNA sequencing. (A) Schematic showing the full study design. Step 1: Three rodent models of epilepsy were generated:
IAKA (intraamygdala kainic acid-induced status epilepticus in C57BL/6 mice), PILO (pilocarpine-induced status epilepticus in NMRI mice), and PPS (perforant
pathway stimulation-induced hippocampal lesioning in Sprague-Dawley rats). Step 2: Hippocampi were extracted at six (mice) or seven (rat) time points and
processed for Ago2 immunoprecipitation and small RNA sequencing (Ago2-seq). Step 3: miRNAs with consistent up-regulation in all three models were
selected for an antagomir-based screen for antiseizure phenotypes and neuroprotection. Step 4: Pathway modeling and biophysical analyses were used to
investigate the function of the miRNAs. (B) The read mapping distribution for the three rodent models. Note, the majority of small RNA reads mapped to
miRNAs. (C) Expression of the top 50 miRNAs between the three models showing highly similar expression levels.


































Fig. 2. Extensive dysregulation of Ago2-loaded miRNAs across all phases of epilepsy development. (A) The 50 most significantly differentially expressed
miRNAs are shown as a heatmap covering all samples from IAKA, PILO, and PPS models. Top annotation shows epileptic animals as black and control animals
as gray. Shown are z scores of log2-transformed RPM values. (B) Examples of individual miRNA expression responses from the PPS model. Shown are miR-132
and miR-146 and potential novel epilepsy-associated miRNAs, miR-127, -24, -434, and -410. (C) Clustering analysis shows that miRNAs from the miR-17∼92
cluster peak at the day of first spontaneous seizure (DOFS). miR-142-3p also peaks at DOFS, though not transcribed from the miR-17∼92 cluster. Also shown
are miR-32-5p and miR-190b-5p, both peaking at DOFS.



























the most robust antiseizure phenotypes when targeted (miR-10a-5p,
miR-21a-5p, and miR-142a-5p), we next assessed whether their
knockdown had any adverse effects. We conducted a range of elec-
trophysiological assessments, originally developed for antagomir-
injected rats (30). We prepared ex vivo brain slices from the rats 2
to 4 d after antagomir injection, to coincide with maximal miRNA
knockdown (29). Multiple electrophysiological measurements were
unchanged in antagomir-injected animals, including population
Fig. 3. Identification of common-to-all model miRNAs. (A) Graphs show the overlap of up-and down-regulated miRNAs between the three models at
various phases of epilepsy development. (B) The miRNAs with consistent up-regulation in all three models, common-to-all miRNAs, are further high-
lighted. (C ) Examples of the expression data from the PPS model for the common-to-all miRNAs up-regulated in chronic epilepsy (excluding miR-146a-5p
and miR-132-3p).


































synaptic response to Schaffer collateral stimulation (Fig. 5A), paired
pulse facilitation (Fig. 5 B and C), and action potential properties of
pyramidal neurons (Fig. 5 D and E). Taken together, these studies
indicate that the antiseizure antagomirs have seemingly limited and
specific effects on hippocampal properties in naïve rodents.
Combinatorial miRNA Inhibition Reduces Seizures in Experimental
TLE. Next, we investigated whether targeting the identified miRNAs
could affect spontaneous recurrent seizures. For this we combined
the three most effective antagomirs (targeting miR-10a-5p,
miR-21a-5p, and miR-142a-5p) into a single antagomir mixture
(termed “combi-antimiR”). We confirmed the combi-antimiR
mediated effective silencing of the three miRNA targets, compara-
ble to the individual antagomirs and with no obvious sex difference
(Fig. 6A). When preinjected with combi-antimiR, mice displayed
reduced seizure severity during SE in the IAKA model, in line with
the results of pretreatments targeting the three miRNAs in-
dividually (Fig. 6 B and C and SI Appendix, Fig. S1 A and B). Next,
additional mice were subjected to IAKA and then monitored over
the next 2 wk for spontaneous recurrent seizures (SRSs) (29, 31).
After establishing equivalent baseline rates of SRSs (SI Appendix,
Fig. S2), mice were randomly assigned to scramble or combi-
antimiR posttreatments and SRS monitored over the next week.
Combi-antimiR reduced both the occurrence and severity of sei-
zures when administered as a posttreatment in already-epileptic
mice, 2 wk after SE (Fig. 6 D and E and SI Appendix, Fig. S2C).
Target and Pathway Analysis Combined with RNA-Seq and Proteomics
Reveal a Role for the TGF-β Signaling Pathway in the Antiseizure
Effects of Combi-antimiR. Finally, we sought to identify potential
mechanisms underlying the antiseizure effects of the antagomirs
and combi-antimiR and focused on identifying convergent
pathways for miR-10a-5p, miR-21a-5p, and miR-142a-5p. The
putative mRNA targets of the three miRNAs were identified
using both predicted (miRDiP) (32) and experimentally vali-
dated [miRTarBase (33) and TarBase (34)] datasets. To reduce
the risk of false positives, we applied strict miRNA–target in-
teraction (MTI) filtering conditions based on miRDIP-assigned
confidence levels and type of experimental validation (Methods).
The estimated MTIs for each miRNA, along with brain expres-
sion information for each putative target, are listed in Dataset
S2. We also performed in situ hybridization for miR-10a-5p,
miR-21a-5p, and miR-142a-5p and this suggested neuronal as
well as glial expression (SI Appendix, Fig. S3). While each miRNA
had many unique targets, the three seizure-related miRNAs (miR-
10a-5p, miR-21a-5p, and miR-142a-5p) shared 59 mRNA targets
(Fig. 7A and SI Appendix, Table S3). Nineteen of these were not
targeted by miR-27a-3p or miR-431, indicating that these targets
could be specific to the observed antiseizure effects (Fig. 7A and
SI Appendix, Table S3). Moreover, 48 mRNAs targeted by >1 of
these miRNAs (of a total 525) have previously been associated with
epilepsy, including GABA receptor, sodium, and potassium channel
subunits (SI Appendix, Table S4).
Fig. 4. Seizure phenotype screening of antagomirs. (A) Schematic shows the experimental design. Briefly, mice were equipped for EEG recordings and
underwent intracerebroventricular injection of one of six antagomirs targeting miR-10a-5p, miR-21a-5p, miR-142a-5p, miR-27a-3p, -5p, miR-431-5p, miR-212-
3p, or controls (PBS or scrambled antagomir). After 24 h, SE was induced (IAKA model) followed by lorazepam (Lz) to reduce mortality and morbidity.
Hippocampal neuronal death was assessed at 24 h after SE. (B) Custom-made antagomir sequences. Capital letters represent LNAs and small letters, DNA
phosphorothioates. (C) Representative traces show EEG recordings over time (starting from IAKA injection) for each group. (D) Graph shows EEG total power
during SE as a percentage of each animal’s own baseline. Mice pretreated with antagomirs for miR-10a-5p, miR-21a-5p, or miR-142a-5p displayed reduced
seizure severity when compared to PBS or scramble controls. (E) Graph shows seizure burden (time in ictal activity) for each group. (F) Representative
photomicrographs and (G) graph from the dorsal ipsilateral hippocampus of mice 24 h after status epilepticus, stained using the irreversible damage marker
Fluoro-jade B (FjB). (Scale bar, 100 μm). All error bars shown as mean ± SEM. n = 9 to 10/group; *P < 0.05, **P < 0.01, ***P < 0.001 compared either to PBS or
Scr by one-way ANOVA with Bonferroni post hoc test.



























We next performed Reactome pathway enrichment analysis
on the predicted targets for each of the miRNAs, using targets
expressed in the hippocampus, and found that 15 pathways were
enriched for targets of more than one seizure-modifying miRNA
(Fig. 7B). Notably, six of these pathways are associated with TGF-β
signaling, including the two pathways enriched in targets of all three
miRNAs (“R-HSA-170834: Signaling by TGF-beta receptor com-
plex” and its daughter pathway “R-HSA-2173793: Transcriptional
activity of SMAD2/SMAD3:SMAD4 heterotrimer”). On further
investigation, we noted that 35/73 genes involved in these two
pathways are targeted by at least one of the seizure-modifying
miRNAs, including TGF-β receptor type 2 (TGFβRII) (Fig. 7C).
To corroborate these systems-level predictions, we combined
RNA-sequencing and mass spectrometry proteomic analyses on
hippocampi isolated at the chronic time point (PPS model). This
identified significant changes in the expression of multiple
components involved in TGF-β signaling. Interestingly, all sig-
nificantly dysregulated TGF-β-associated mRNAs were down-
regulated (Fig. 7D and Dataset S3), and the main proteomic
changes observed were down-regulated in the range of 0.7 to 0.9
fold change (FC) (Fig. 7E and Dataset S4). This is consistent
with the actions of miRNAs to fine tune expression levels of
targets in the same pathway. The majority of the significantly
down-regulated mRNAs and proteins in the TGF-β signaling
pathway are targeted by one or more of the three identified
miRNAs as depicted in Fig. 7C. This led to a testable prediction
that derepression of TGF-β signaling may be a convergent
mechanism of the targeted miRNAs. We therefore measured
levels of pathway components in mice that had previously received
either scramble or the combi-antimiR 24 h before SE (Fig. 6B).
Western blotting revealed TGFβRII protein levels were higher in
mice treated with the combi-antimiR compared to scrambled con-
trols (Fig. 7F and SI Appendix, Fig. S1C). To extend this, we coin-
jected the TGF-β pathway inhibitor galunisertib (2 mg/kg
intraperitoneally [i.p.]), or vehicle control, with combi-antimiR be-
fore SE. Seizure severity was increased in combi-antimiR-treated
mice coadministered galuninisertib compared to vehicle (Fig. 7G),
providing additional evidence for a role of TGF-β signaling in the
therapeutic effects of the antagomirs.
Discussion
The existence of conserved miRNA signatures in the develop-
ment and maintenance of a seizure-prone state would provide
important mechanistic insights and guide prioritization of miRNAs
for therapeutic targeting. Here we undertook a coordinated effort,
sequencing Ago2-bound miRNA to more accurately predict the
regulatory potential of a given miRNA than by measuring overall
miRNA levels in a sample (24), covering three different models,
two species, and all stages from the initial precipitating insult to
establishment of spontaneous recurrent seizures. The dataset
contains robust statistics and fold change for individual miRNAs
at each time point to illustrate expression variance and cross-model
and cross-species comparisons. We found high concordance between
the models and species in expression of known brain-enriched
Fig. 5. Antagomir effects on hippocampal biophysics in naïve animals. (A) Stimulus–response curves. We stimulated the Schaffer collateral pathway in the
hippocampus and recorded the population synaptic response in CA1 stratum radiatum (Left schematic). Robust responses were observed in all treatment
groups (Middle Left) and no significant differences in excitability were seen between groups (Right; mixed ANOVA, P > 0.05). (B) Paired-pulse facilitation. We
used the same electrode configuration as A but this time delivered two pulses (generating a response that was 30% of the maximum) at varying intervals.
Robust facilitation was seen in all groups (B, representative raw data for 50-ms stimulation interval) with no clear differences between groups (C, mixed
ANOVA, P > 0.05). (D) Single cell biophysics. We made current clamp recordings from CA1 pyramidal neurons and injected a current step protocol (−100 to
+400 pA, 25-pA increments, 100-ms step duration). Raw data show the threshold action potential from each neuron. Total numbers of rats and cells used for
each group are listed. (E) There were no differences in any passive properties (resting membrane potential [RMP] and input resistance scatterplots) or in
properties of the threshold action potentials (all one-way ANOVA with Bonferroni post hoc test, P > 0.05).


































miRNAs, including miR-128-5p (35) and members of the let-7 family
(36) whereas no reads were detected for nonbrain miRNAs such as
miR-122-3p (liver specific) and miR-208b-3p (heart specific) (37, 38).
The dataset features expected changes to neuronal activity-regulated
miRNAs, including miR-132-3p (25) and miRNAs that regulate
cellular responses to tissue injury, such as apoptosis-associated
miR-34a-5p (39, 40). Together, the results offer important ad-
vances over previous work which focused on predetermined
miRNAs (e.g., microarray based), lacked quantitative information on
relative abundance, and lacked functional relevance (non-Ago2-loaded
miRNAs) (21, 25, 41–45). The Ago2-sequencing (Ago2-seq)
data provided in the current study are also an important com-
panion to other databases on miRNA–epilepsy associa-
tions (46). The data complement, as well as reveal distinct
profiles from Ago2-seq analysis of neural precursors (47) and
should interest researchers working on disease mechanisms for
which there is shared pathophysiology, such as traumatic brain
injury (48).
By employing a multimodel sequencing approach, we were
able to demonstrate that there are shared miRNAs dysregulated
at all phases in the development of epilepsy, up to and including
the period of active chronic epilepsy. Most of the miRNA
changes fell within a 1.5- to 3-fold range although some, in-
cluding miR-142a-5p, displayed much larger fold changes. There
was no apparent species or model-specific bias, and numbers of
shared miRNAs at the different stages of epilepsy development
were quite similar, ranging from 6 to 18 among up-regulated
miRNAs. We detected previously reported changes to miRNAs
functionally linked to experimental epilepsy, including miR-22-
3p (49), miR-129-5p (50), miR-134-5p (25), miR-146a-5p (27),
and miR-324-5p (51). This indicates that Ago2-seq identifies robust
miRNAs for targeting, a means to cross-compare between species
and model, and a way to better prioritize miRNAs for functional
assessment. A number of the miRNAs reported to be dysregulated
in human TLE (52–54) were also differentially expressed in the
chronic epilepsy state. This underscores the clinical relevance and
translatability of our findings. It also invites additional predictions
about human-dysregulated miRNAs which might be tested for
function in animal models. The results extend evidence of a com-
mon miRNA signature in experimental epileptogenesis (23), con-
trasting conclusions from certain metaanalyses (22). Moreover, we
report higher numbers of miRNAs and more differentially
expressed miRNAs across these animal models than any previous
epilepsy profiling study (21, 25, 41–45), indicating that miRNA
dysregulation may impact on gene expression even more extensively
than previously thought (17).
The potential for a miRNA-based therapeutic is gaining
traction for disease modification in epilepsy (5, 17). LNA-based
oligonucleotides as used here are particularly relevant for clinical
translation as this backbone chemistry has been used in human
trials of a miRNA-based therapy for hepatitis C (55). Here we
show that robust antiseizure and neuroprotective effects can be
achieved by targeting multiple miRNAs commonly up-regulated
at the stage of chronic epilepsy. Notably, this included miRNAs
Fig. 6. Combi-antimiR suppresses seizures in established epilepsy. (A) Relative levels of miRNAs measured 24 h after injection of combi-antimiR, confirming
effective inhibition of all three targeted miRNAs (closed circles, male mice; open circles, female mice, pooled for statistics; all t test *P < 0.05, **P < 0.01; n = 5
mice [scramble] and 6 mice [combi-antimiR]). (B) Representative EEGs during SE induced by IAKA in mice pretreated 24 h previously with scramble or combi-
antimiR (#, EEG artifacts [excluded from analysis]). (C) Scatterplot showing total EEG power during SE for all mice pretreated with combi-antimiR (closed
circles, male mice; open circles, female mice, pooled for statistics; t test ****P < 0.0001, n = 11 mice per group). (D) Representative EEGs showing typical
spontaneous recurrent seizure (SRS) in epileptic mice posttreated 2 wk after SE with either scramble or combi-antimiR. (E) Scatterplots show posttreatment of
epileptic mice with combi-antimiR reduced EEG power during ictal periods and the number of SRS per hour averaged during the recording period compared
to scramble (all t test, α-corrected to 0.025 for multiple testing, ictal power posttreatment P = 0.0061, number of SRS posttreatment, P = 0.011).



























for which there was no prior knowledge of a functional link to
epilepsy. From these, we selected miRNAs which were fully con-
served in humans, enhancing the translational potential of our
findings. Our unbiased screen for antiseizure phenotypes identified
five antagomirs that protect the brain against prolonged seizures, of
which those targeting miR-10a-5p, miR-21a-5p, and miR-142a-5p
had the most robust effects. Additionally, a combi-antimiR target-
ing all three miRNAs reduced spontaneous recurrent seizures when
administered as a posttreatment to mice which had developed ep-
ilepsy. Taken together, this is a substantial addition to the number
of miRNAs reported as potential targets for seizure control (20). It
also suggests that many of the up-regulated miRNAs in the chronic
epilepsy phase may be suppressing targets that would otherwise
oppose hyperexcitability. While the antiseizure effects of targeting
miR-10a-5p, miR-142a-5p, and the neuroprotection associated with
inhibition of miR-431-5p have not previously been described, a
recent study also found that targeting miR-21-5p could suppress
seizures (56). Notably, our biophysical analyses of the electrophys-
iological properties of hippocampus from antagomir-treated rodents
showed no obvious impairments. Together, these findings suggest
broad safety and suitability to enter preclinical development.
The regulatory potential of miRNAs is enhanced where there
is convergence upon a small number of targets or pathways (11,
12). An important effort in the present study was to combine
mRNA targets of all miRNAs (experimentally validated and
predicted interactions) to build superior pathways, building in a
high-confidence threshold for target predictions. We found that
the three seizure-regulating miRNAs converge on the TGF-β
signaling pathway. Analyses at the mRNA and protein levels
corroborated this pathway-level effect. Treatment with combi-
antimiR derepressed TGFβRII, a validated target of both miR-
21 (57) and miR-142 (58), while inhibition of TGF-β signaling
occluded the antiseizure effect of combi-antimiR. These results
implicate TGF-β signaling as an underlying therapeutic target
mechanism. This is consistent with evidence that genetic defects in
the TGF-β pathway can cause epilepsy in humans (59), although
excessive TGF-β signaling has been implicated in epileptogenesis
(60). Other overlapping targets, including ion channels and several
Fig. 7. Target identification and pathway enrichment analysis identified TGF-β signaling as a potential convergent mechanism of the seizure-modifying
miRNAs. (A) Number of mRNAs targeted by each miRNA. One mRNA (thyroid hormone receptor beta) is targeted by all 5 miRNAs. A total of 59 mRNAs are
targeted by the 3 seizure-modifying miRNAs, 19 of which are not targeted by either miR-27a-3p or miR-431 (SI Appendix, Table S3). All targets are listed in
Dataset S2. (B) Significantly enriched Reactome pathways for each of the seizure-modifying miRNAs. ** indicates pathways associated with TGF-β signaling.
(C) Wiring diagram depicting mRNA targets of the 3 seizure-modifying miRNAs that are involved in the Reactome pathways: signaling by TGF-beta receptor
complex and transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer, illustrating the convergence of diverse miRNA targets at the pathway level. (D)
mRNA expression levels (normalized to control) of rat hippocampi isolated at the chronic time point of the PPS model. mRNAs above the dashed lines (drawn
at −log10[q value] = 1.3 and 2.0) were considered statistically significant. Fold changes are shown on the x axis with significantly dysregulated mRNAs involved in the
TGF-β signaling pathways highlighted in blue (all down-regulated). * denotes mRNAs which are targeted by miR-10a-5p, miR-21-5p, and/or miR-142-5p, as depicted in
C. (E) Protein expression levels (normalized to control) of rat hippocampi isolated at the chronic time point of the PPS model. Proteins above the dashed lines (drawn
at −log10[q value] = 1.3 and 2.0) are considered statistically significant. Fold changes are shown on the x axis with proteins involved in the TGF-β signaling pathways
are highlighted in blue (down-regulation) and red (up-regulation). * denotes proteins which are targeted by miR-10a-5p, miR-21-5p, and/or miR-142-5p, as depicted in
C. (F) Graph showing semiquantification of Western blot analysis of mouse brains taken 24 h after IAKA-induced SE shows that pretreament with combi-antimiR
derepresses TGFβRII expression. Brain tissue samples were from mice in Fig. 6B, where combi-antimiR pretreatment reduced SE. (G) Coadministration of the TGF-β
pathway inhibitor galunisertib occludes the antiseizure effect of combi-antimiR. (Left) Raw EEG traces show SE induced by IAKA inmice pretreated with combi-antimiR
and galunisertib (blue trace) or vehicle control (red trace). (Right) TGF-β pathway inhibition with galunisertib blocks the antiseizure effects of combi-antimiR pre-
treatment (#, EEG artifact [excluded from analysis], n = 6 mice per group, t test *P < 0.05).


































of the genes targeted by two or all three of the seizure-regulating
miRNAs, have previously been implicated in epilepsy.
There are some limitations and assumptions to consider in the
present study. Some of the Ago2-bound miRNA pool may not be
actively engaged with mRNA targets (61), Ago isoforms besides
Ago2 may be important (14) and small RNA sequencing may
over- or underestimate the abundance of certain miRNA species
(62). We restricted our functional studies to targeting up-
regulated miRNAs using antisense oligonucleotides. This has
broad safety relative to overexpressing miRNAs which could sat-
urate the RNA interference pathway (63), but down-regulated
miRNAs may also represent therapeutic targets (23). Notably,
target RNA-directed miRNA degradation (TDMD) has been
reported, whereby miRNAs themselves are degraded upon bind-
ing a target site of high complementarity (64, 65). However, this
has rarely been seen with endogenous target RNAs and we did not
find evidence that the levels of the three miRNAs of main focus
were influenced by TDMD (SI Appendix, Fig. S4). Another
mechanism by which miRNA function can be reduced is via cir-
cular RNA (circRNA), which binds specific miRNAs rendering
the bound miRNAs inactive, and studies have found circRNA
levels to be altered in epilepsy (66). Adjustment of criteria
for selecting miRNAs could yield additional miRNAs for func-
tional studies. Indeed, several potentially new epilepsy-associated
miRNAs not identified in multimodel or metaanalyses of miRNAs
(21–23) showed significant regulation in two of the models here,
including highly expressed miRNAs (thus likely to be functionally
significant) such as miR-410-3p and miR-434-3p (down-regulated)
and miR-24-3p and miR-127-3p (up-regulated). Primate or human-
specific miRNAs would not have been detected by our screen and
may represent additional therapeutic targets. Finally, genetic vari-
ation in miRNA coding regions could affect expression. However,
the common-to-all miRNAs here do not originate from genomic
regions known to have chromosomal mutations in epilepsy (67, 68).
Large-scale DNA sequencing is warranted to test the impact of
genetic variation on miRNA function in epilepsy covering coding
genomic regions, miRNA processing genes, and miRNA target sites
on mRNAs.
Conclusions
The present study generated a unique resource to explore the
expression and dysregulation of miRNAs across multiple animal
models of epilepsy and throughout the course of the disease.
This systematic approach to discovery revealed a greater than
previously anticipated, temporally specific dysregulation of miRNAs
in epilepsy and showed this to be a rich source of seizure-regulatory
miRNA targets. We identified multiple additional miRNA targets
for seizure control, likely mediated through derepression of TGF-β
signaling. Together, these results reinforce and extend the evidence
that miRNAs are a major class of regulatory element in epilepsy
with therapeutic potential for seizure control.
Methods
Animal Models of Epilepsy. All animal experiments were performed in ac-
cordance with the European Communities Council Directive (2010/63/EU). All
animals were housed in on-site barrier-controlled facilities having a 12-h
light–dark cycle with ad libitum access to food and water.
Procedures in rats were approved by the local regulation authority
(Philipps University Marburg, Germany: Regierungspraesidium Giessen, 73/
2013), or according to the Animals (Scientific Procedures) Act 1986 (United
Kingdom). Male Sprague-Dawley rats (325 to 350 g [Charles River] or 200 to
300 g [Harlan]) were used in all studies. Epilepsy was induced using PPS in
rats, as described (69) and detailed in SI Appendix, Supplementary Methods.
Rats were killed under deep anesthesia (xylazine + ketamine) by transcardial
perfusion with ice-cold 0.9% NaCl solution at the following time points: 1 h,
24 h, 72 h, 10 d, and 16 d after PPS (epileptogenesis); within 1 d of first spon-
taneous seizure (early epilepsy); or 1 mo after first spontaneous seizure (chronic
epilepsy). Control rats were killed on day 17 after surgery (corresponding to day
10 after PPS). Hippocampi were removed and snap frozen at −80 °C.
Procedures for inducing epilepsy using the IAKA technique in mice were
approved by the Research Ethics Committee of the Royal College of Surgeons
in Ireland (REC-842), under license from the Health Products Regulatory
Authority (AE19127/001), Dublin, Ireland. Adult male C57BL/6 mice (20 to
25 g [Harlan]) were used, as described (70) and detailed in SI Appendix,
Supplementary Methods. Mice were killed at 1 h, 24 h, 48 h, 72 h, day of first
spontaneous seizure (typically 3 to 5 d after SE), or at 2 wk (chronic epilepsy).
At the time of killing, mice were deeply anesthetized with phenobarbital
and transcardially perfused with ice-cold PBS to remove blood contaminants.
Hippocampi were frozen and stored at −80 °C.
Procedures for inducing epilepsy using the PILO model in mice were ap-
proved by the University of Verona Research Ethics Committee under license
from the Italian Ministry of Health (27/2014-PR). Adult male NMRI mice
(Harlan) were used, as detailed in SI Appendix, Supplementary Methods.
Mice were killed at 1 h, 24 h, 48 h, 72 h, day of first spontaneous seizure
(typically 1 to 2 w after SE), or at 4 wk (chronic epilepsy).
Immunoprecipitation of Ago2, RNA Extraction, and Sequencing (Ago2-Seq).
Frozen hippocampi were thawed on ice. Tissue was homogenized in
200 μL of immunoprecipitation (IP) buffer (300 mM NaCl, 5 mM MgCl2, 0.1%
Nonidet P-40, 50 mM Tris·HCl pH 7.5, protease and RNase inhibitors). The
homogenate was centrifuged at 16,000 × g for 15 min at 4 °C to pellet nuclei
and membranes. Supernatant (considered total cell lysate) was transferred
to a clean Eppendorf tube. Bradford assay was performed to quantify pro-
tein content of total cell lysate. The lysate was precleared by adding 10 μL of
50% Protein A/G beads (Santa Cruz Biotechnology) to 400 μg of protein
lysate, final volume was adjusted to 1 mL using IP buffer, and lysate was
incubated rotating for 1 h at 4 °C, then centrifuged at 13,000 × g for 5 min at
4 °C to pellet the beads, and supernatant was transferred to a new Eppen-
dorf tube. A total of 5 μg (5 μL of AGO-2, Cell Signaling Cat. No. 2897) an-
tibody was added to precleared cell lysate, vortexed, and incubated rotating
overnight at 4 °C. A total of 20 μL of 50% A/G agarose beads was added to
lysate antibody solution and incubated, rotating for 2 h at 4 °C, then
centrifuged at 16,000 × g for 15 min at 4 °C, and supernatant removed. The
pellet was washed twice with 500 μL IP buffer by gently resuspending pellet,
centrifuging at 16,000 × g for 1 min at 4 °C, and removing supernatant.
TRIzol RNA purification was performed after which pelleted RNA was dis-
solved in 12 μL dH20 and heated to 60 °C for 10 min. Purified RNA was stored
at −80 °C until small RNA library preparation. A total of 5 μL of purified RNA
was prepared using TruSeq small RNA library preparation kit (Illumina), for
rat samples, using standard procedure and 12 PCR cycles and for mouse,
using half the amount of primers and reagents and 15 PCR cycles. Pippin
prep (Sage Science) was used to size fractionate libraries to the 140-bp to
160-bp size range. Library size and purity was validated on a Bioanalyzer
2100 (Agilent) using a high-sensitivity DNA chip, and the concentration was
quantified using a KAPA Library Quantification Kit. Prepared libraries were
pooled as required and sequenced on a NextSeq500 (Illumina) at Exiqon.
Analysis of Small RNA Sequencing Data. FASTX-Toolkit was used to quality-
filter reads and cutadapt was used to remove adaptor sequences. Filtered
reads were mapped using Bowtie to a list of datasets. First, reads were
mapped to miRNAs from miRBase v21 allowing zero mismatches, but allowing
for nontemplated 3′ A and T bases. Reads not mapping to miRNAs were
mapped against other relevant small RNA datasets: piRNA, tRNA, snRNA,
snoRNA, and Y RNA allowing one mismatch. The remaining unmapped reads
were mapped to mRNA and rRNA datasets. miRNAs were normalized as reads
per million miRNA mapping reads (RPM). Statistical significance was calculated
by one-way ANOVA with false discovery rate (FDR) (Benjamini–Hochberg).
Common-to-all miRNAs were defined as having mean basal expression above
10 RPM, while exhibiting same-directional expression change of 25% or higher
in all three models at key time points, as detailed above for each model.
Systematic Antagomir Screening. Antagomir screening was performed in the
IAKA mouse model according to previously described techniques (71) and
detailed in SI Appendix, Supplementary Methods. An additional subset of
adult female C57BL/6 mice (Harlan, weight matched to males [20 to 25 g],
coordinates for IAKA verified by ink injection) were used in some experi-
ments. For pretreatment studies, antagomirs or combi-antimiR (SI Appendix,
Supplementary Methods) were administered 24 h before SE induction by
IAKA. A subset of mice were given the TGFβRI/II inhibitor galunisertib (Tocris,
Cat. No. 6956, 2 mg/kg via i.p. injection; vehicle, 10% dimethyl sulfoxide in
PBS). A first galunisertib injection was given at the same time as combi-
antimiR, 24 h before SE, and a second injection of galunisertib alone was
given 30 min before SE. Twenty-four hours after SE, mice were transcardially
perfused and brains removed for histopathological analysis of hippocampal



























damage or molecular analysis. Seizure-induced neuronal damage was ana-
lyzed on 12-μm coronal sections at the level of medial hippocampus
(AP = −1.70 mm) using Fluoro-Jade B (FJB) (Millipore Ireland B.V.) as de-
scribed (70). For posttreatment study, combi-antimiR was given 14 d after
induction of SE by IAKA and mice were perfused 21 d after SE.
RNA Extraction and RT-qPCR to Assess Antagomir-Mediated miRNA Knockdown.
Hippocampi were homogenized in 750 μL of TRIzol and centrifuged at
12,000 × g for 10 min at 4 °C. Phase separation was performed by adding 200 μL
of chloroform to each sample and vigorously mixing for 15 s before incubating
at RT. Samples were centrifuged at 15,600 × g for 15 min at 4 °C. The upper
phase was removed and 450 μL of isopropanol was added and samples were
stored at −20 °C overnight. Samples were centrifuged at maximum speed for
30 min at 4 °C. A total of 750 μL of 75% cold ethanol was used to wash the
pellet. Samples were centrifuged at 13,300 × g for 5 min and the ethanol was
removed. This step was repeated twice. The pellets were left to dry for 1 h and
resuspended in 25 μL of RNase free H20. Samples were incubated for 10 min at
60 °C with 60 × g of agitation. Samples were stored at −80 °. A total of 500 ng
was reverse transcribed using stem-loop Multiplex primer pools (Applied Bio-
systems). We used reverse-transcriptase-specific primers for the hsa-miR-10a
(Applied Biosystems miRNA assay ID 000387), hsa-miR-21a (Applied Biosystems
miRNA assay ID 000397), and hsa-miR-142a (Applied Biosystems miRNA assay ID
002248) and real-time quantitative PCR was carried out on a 7900HT Fast Real-
time System (Applied Biosystems) using TaqMan miRNA assays (Applied Bio-
systems). U19 (Applied Biosystems miRNA assay ID 001003) was used for
normalization. A relative fold change in expression of the target gene transcript
was determined using the comparative cycle threshold method (2-ΔΔCT).
In Vitro Assay of Effects of Anti-miR-10a-5p, Anti-miR-21a-5p, and Anti-miR-142a-5p.
Stereotaxic injection for each miRNA knockdown was performed on adult male
Sprague–Dawley rats (weight range 270 to 380 g) as described previously (30)
and detailed in SI Appendix, Supplementary Methods. Ex vivo brain slices were
prepared between 2 and 4 d after surgery, to coincide with the maximal miRNA
silencing effect (30). All slice electrophysiology was performed using a mem-
brane chamber (30) perfused with oxygenated recording artificial cerebrospinal
fluid (ACSF), heated to 34 °C, at a rate of 16 mL min−1. Electrophysiological data
were filtered at 10 kHz using a Multiclamp 700B amplifier (Molecular Devices),
digitized at 10 kHz with a Power1401 (Cambridge Electronic Design), and
recorded using Signal software (Cambridge Electronic Design). For extracellular
recordings, we stimulated the Schaffer Collateral pathway with a concentric
bipolar stimulating electrode (FHC, CBARC75) and recorded the response in CA1
stratum radiatum using a thin-walled borosilicate glass microelectrode (∼5 MΩ)
filled with recording ACSF (in mM: 125 NaCl, 10 glucose, 26 NaHCO3, 1.25
NaH2PO4.H2O, 3 KCl, 2 CaCl2, 1 MgCl2). Patch clamp recordings used ∼5-MΩ glass
microelectrodes filled with intracellular solution (in mM: 135 K-gluconate, 4 KCl,
10 Hepes, 4 Mg-ATP, 0.3 Na-GTP, 10 Na2-phosphocreatine; pH 7.3; 290 mOsm).
After at least 5 min, neurons were injected with a series of hyperpolarizing and
depolarizing current steps (100-ms current injections with 1 s between
steps; −100 to +400 pA in 25-pA increments). The first action potential elicited by
a depolarizing step was selected for analysis. All recordings were made with
bridge balance compensated, access resistance <20 MΩ, and rejected if action
potentials did not overshoot 0 mV.
Bioinformatics: mRNA Target Identification, miRNA Target Interaction (MTI)
Prioritization, and Pathway Enrichment Analysis. Predicted MTIs were down-
loaded frommiRDiP V4.1, a database that integrates 30 prediction algorithms
and calculates an MTI confidence score based on statistical inference (32).
Experimentally validated MTIs were downloaded from miRTarBase V7 (33)
and TarBase V7.0 (34). To ensure interoperability, all miRNA names were
translated to miRBase V22 using miRNAmeConverter (72) and mRNA names
were converted to official gene symbols using Ensembl V91. Nonhuman MTIs
were excluded to constrain analyses to putative translatable mechanisms.
Strict filtering criteria were devised to prioritize MTIs and reduce the risk of
false-positive MTI identification; predicted MTIs were retained only if their
miRDIP-assigned confidence levels were “very high,” while experimentally
validated MTIs were excluded if the only form of validation was high-
throughput CLiP experiments performed prior to 2013, as these are con-
sidered less reliable due to poor antibody specificity and RNA contamination
(73). Baseline mRNA tissue expression information were from the GTEx-EBI
Expression Atlas (74) and transcription factor information from TRRUST V2.0
[https://www.grnpedia.org/trrust/], ENCODE (75), and ChEA (76).
mRNAs implicated in epilepsy were identified using an in-house database
collating information from CARPEDB [http://carpedb.ua.edu], epiGAD (77),
Wang et al. (78), and curated epilepsy genes from the Comparative
Toxicogenomics Database (CTD) (79).
Pathway analysis was performed on Reactome pathways containing 10 to
500 genes by applying the cumulative hypergeometric distribution for P value
comparison (80). Pathways with corrected P values of <0.05 (Benjamini–
Hochberg) were considered significantly enriched.
RNA Sequencing (mRNA). RNA was rRNA depleted using the Ribo-Zero
Magnetic Kit (human/mouse/rat; Illumina). Sequencing libraries were gen-
erated using the ScriptSeq v2 kit (Illumina), quality controlled on the 2100
Bioanalyzer (Agilent). Sequencing was done on an Illumina HiSeq sequencer.
Sequencing data were quality controlled and adaptor trimmed using Trim
Galore. Filtered data were mapped to the rat genome Rn6 using TopHat2.
Cufflinkswasused to assemble transcripts from themapped reads guidedbygene
annotation from Ensembl Release 87. Cuffmerge, cuffquant, and cuffdiff (part of
the Cufflinks software package) were used to quantify transcript abundance in
each sample and to perform differential expression analysis of genes and gene
isoforms. P values were corrected for multiple testing using Benjamini–Hochberg
correction.
Proteomic Analysis. Hippocampi for proteomic analysis were taken from rats
at the chronic time point of the PPS model and processed as detailed in SI Ap-
pendix, Supplementary Methods. Differential expression was evaluated using a
combined limma and rank product test to obtain q values for each protein.
Volcano plots were created by plotting log2 average ratios against −log10 q
values obtained in the above-mentioned limma and rank product test.
Statistics. For Ago2-seq, statistical significance was calculated by one-way
ANOVA with FDR (Benjamini–Hochberg). In vivo seizure screening used
one-way ANOVA with Bonferroni post hoc correction. Ex vivo slice experi-
ments used unpaired t test, one-way ANOVA, or mixed ANOVA, as appro-
priate. The statistical approaches for pathway analysis, mRNA sequencing,
and proteomics are detailed above.
Availability of Data and Materials. The sequencing data have been deposited
to the Gene Expression Omnibus (GEO) under accession no. GSE137473 (81).
The proteomics data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the dataset identifier
PXD019098 (82). Custom analysis codes are available on https://github.com/
g-morris/Ago2Seq. All data generated or analyzed during this study are in-
cluded in this published article (and its SI Appendix files). For questions on
the MTI analysis, contact jprehn@rcsi.ie.
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42. A. M. Bot, K. J. Dȩbski, K. Lukasiuk, Alterations in miRNA levels in the dentate gyrus in
epileptic rats. PLoS One 8, e76051 (2013).
43. J. A. Gorter et al., Hippocampal subregion-specific microRNA expression during epilepto-
genesis in experimental temporal lobe epilepsy. Neurobiol. Dis. 62, 508–520 (2014).
44. M. M. Li et al., Genome-wide microRNA expression profiles in hippocampus of rats
with chronic temporal lobe epilepsy. Sci. Rep. 4, 4734 (2014).
45. P. Roncon et al., MicroRNA profiles in hippocampal granule cells and plasma of rats
with pilocarpine-induced epilepsy–Comparison with human epileptic samples. Sci.
Rep. 5, 14143 (2015).
46. C. Mooney, B. A. Becker, R. Raoof, D. C. Henshall, EpimiRBase: A comprehensive da-
tabase of microRNA-epilepsy associations. Bioinformatics 32, 1436–1438 (2016).
47. X. S. Liu et al., Identification of miRNomes associated with adult neurogenesis after
stroke using Argonaute 2-based RNA sequencing. RNA Biol. 14, 488–499 (2017).
48. A. K. Liou, R. S. Clark, D. C. Henshall, X. M. Yin, J. Chen, To die or not to die for neurons in
ischemia, traumatic brain injury and epilepsy: A review on the stress-activated signaling
pathways and apoptotic pathways. Prog. Neurobiol. 69, 103–142 (2003).
49. E. M. Jimenez-Mateos et al., microRNA targeting of the P2X7 purinoceptor opposes a
contralateral epileptogenic focus in the hippocampus. Sci. Rep. 5, 17486 (2015).
50. M. Rajman et al., A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic
downscaling of excitatory synapses. EMBO J. 36, 1770–1787 (2017).
51. C. Gross et al., MicroRNA-mediated downregulation of the potassium channel Kv4.2
contributes to seizure onset. Cell Rep. 17, 37–45 (2016).
52. P. Bencurova et al., MicroRNA and mesial temporal lobe epilepsy with hippocampal scle-
rosis: Whole miRNome profiling of human hippocampus. Epilepsia 58, 1782–1793 (2017).
53. S. F. Miller-Delaney et al., Differential DNA methylation profiles of coding and non-
coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain
138, 616–631 (2015).
54. A. A. Kan et al., Genome-wide microRNA profiling of human temporal lobe epilepsy
identifies modulators of the immune response. Cell. Mol. Life Sci. 69, 3127–3145
(2012).
55. H. L. Janssen et al., Treatment of HCV infection by targeting microRNA. N. Engl.
J. Med. 368, 1685–1694 (2013).
56. C. Tang et al., Targeting of microRNA-21-5p protects against seizure damage in a
kainic acid-induced status epilepticus model via PTEN-mTOR. Epilepsy Res. 144, 34–42
(2018).
57. T. Papagiannakopoulos, A. Shapiro, K. S. Kosik, MicroRNA-21 targets a network of key
tumor-suppressive pathways in glioblastoma cells. Cancer Res. 68, 8164–8172 (2008).
58. Z. Ma et al., MicroRNA regulatory pathway analysis identifies miR-142-5p as a negative
regulator of TGF-β pathway via targeting SMAD3. Oncotarget 7, 71504–71513 (2016).
59. D. Kotlarz et al., Human TGF-β1 deficiency causes severe inflammatory bowel disease
and encephalopathy. Nat. Genet. 50, 344–348 (2018).
60. S. Ivens et al., TGF-beta receptor-mediated albumin uptake into astrocytes is involved
in neocortical epileptogenesis. Brain 130, 535–547 (2007).
61. G. La Rocca et al., In vivo, Argonaute-bound microRNAs exist predominantly in a
reservoir of low molecular weight complexes not associated with mRNA. Proc. Natl.
Acad. Sci. U.S.A. 112, 767–772 (2015).
62. D. Leshkowitz, S. Horn-Saban, Y. Parmet, E. Feldmesser, Differences in microRNA
detection levels are technology and sequence dependent. RNA 19, 527–538 (2013).
63. M. A. van Gestel et al., shRNA-induced saturation of the microRNA pathway in the rat
brain. Gene Ther. 21, 205–211 (2014).
64. M. de la Mata et al., Potent degradation of neuronal miRNAs induced by highly
complementary targets. EMBO Rep. 16, 500–511 (2015).
65. A. Bitetti et al., MicroRNA degradation by a conserved target RNA regulates animal
behavior. Nat. Struct. Mol. Biol. 25, 244–251 (2018).
66. G. H. Gong et al., Comprehensive circular RNA profiling reveals the regulatory role of
the CircRNA-0067835/miR-155 pathway in temporal lobe epilepsy. Cell. Physiol. Bio-
chem. 51, 1399–1409 (2018).
67. Epi4K consortium; Epilepsy Phenome/Genome Project, Ultra-rare genetic variation in
common epilepsies: A case-control sequencing study. Lancet Neurol. 16, 135–143 (2017).
68. C. Leu, A. Coppola, S. M. Sisodiya, Progress from genome-wide association studies and
copy number variant studies in epilepsy. Curr. Opin. Neurol. 29, 158–167 (2016).
69. B. A. Norwood et al., Classic hippocampal sclerosis and hippocampal-onset epilepsy
produced by a single “cryptic” episode of focal hippocampal excitation in awake rats.
J. Comp. Neurol. 518, 3381–3407 (2010).
70. G. Mouri et al., Unilateral hippocampal CA3-predominant damage and short latency
epileptogenesis after intra-amygdala microinjection of kainic acid in mice. Brain Res.
1213, 140–151 (2008).
71. C. R. Reschke et al., Potent anti-seizure effects of locked nucleic acid antagomirs
targeting miR-134 in multiple mouse and rat models of epilepsy. Mol. Ther. Nucleic
Acids 6, 45–56 (2017).
72. S. J. Haunsberger, N. M. Connolly, J. H. Prehn, miRNAmeConverter: An R/bioconductor
package for translating mature miRNA names to different miRBase versions. Bio-
informatics 33, 592–593 (2017).
73. M. J. Moore et al., Mapping Argonaute and conventional RNA-binding protein in-
teractions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis.
Nat. Protoc. 9, 263–293 (2014).
74. European Molecular Biology Laboratory, RNA-seq from 53 human tissue samples from
the Genotype-Tissue Expression (GTEx) Project. Expression Atlas. https://www.ebi.ac.
uk/gxa/experiments/E-MTAB-5214/Results. Accessed 5 April 2018.
75. Ma’ayan Laboratory of Computational Systems Biology, ENCODE transcription factor
targets. Harmonizome. http://amp.pharm.mssm.edu/Harmonizome/dataset/ENCODE+
Transcription+Factor+Targets. Accessed 13 October 2018.
76. Ma’ayan Laboratory of Computational Systems Biology, CHEA transcription factor
targets. Harmonizome. http://amp.pharm.mssm.edu/Harmonizome/dataset/CHEA+
Transcription+Factor+Targets. Accessed 13 October 2018.
77. N. C. Tan, S. F. Berkovic, The epilepsy genetic association database (epiGAD): Analysis
of 165 genetic association studies, 1996-2008. Epilepsia 51, 686–689 (2010).
78. J. Wang et al., Epilepsy-associated genes. Seizure 44, 11–20 (2017).
79. A. P. Davis et al., The comparative toxicogenomics database: Update 2019. Nucleic
Acids Res. 47, D948–D954 (2019).
80. E. I. Boyle et al., GO:TermFinder—Open source software for accessing Gene Ontology
information and finding significantly enriched Gene Ontology terms associated with
a list of genes. Bioinformatics 20, 3710–3715 (2004).
81. M. Veno, J. Kjems, D. C. Henshall, A systems approach delivers a functional microRNA
catalog and expanded targets for seizure suppression in temporal lobe epilepsy. Gene
Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137473. De-
posited 16 September 2019.
82. J. S. Andersen, A systems approach delivers a functional microRNA catalog and ex-
panded targets for seizure suppression in temporal lobe epilepsy. PRIDE. https://www.
ebi.ac.uk/pride/archive/projects/PXD019098. Deposited 12 May 2020.
15988 | www.pnas.org/cgi/doi/10.1073/pnas.1919313117 Venø et al.
D
ow
nl
oa
de
d 
at
 B
ib
lio
te
ca
 M
en
eg
he
tti
 o
n 
A
ug
us
t 4
, 2
02
0 
